Tava-Floxacin  (Film Coated Tablets)

Broad Spectrum antibacterial

Each film coated tablet contains 250, or 500mg Levofloxacin.

Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class.
Tava-Floxacin is antibacterial agent with activity against wide range of gram-negative and gram-positive organisms. The bactericidal action of Tava-Floxacin results from interference with the activity of the bacterial enzyme DNA gyres, which is needed for the transcription and replication of bacterial DNA.

Tava-Floxacin is indicated for infections of mild to moderate severity, it is indicated for treatment of the following infections when due to levofloxacin susceptible micro-organisms:

  • Acute sinusitis.
  • Acute exacerbation of chronic bronchitis, pneumonia.
  • Complicated urinary tract infections including pyelonephritis.
  • Skin and soft tissue infections.

The dosage depends on the type and severity of the infection and the sensitivity of the presumed causative pathogen.

  • Acute sinusitis: 500mg once daily, for 10 – 14 days.
  • Acute exacerbation of chronic bronchitis: 250 - 500mg once daily, for 7 days.
  • Pneumonia: 500mg once daily, for 7 – 14 days
  • Complicated urinary tract infections including pyelonephritis: 250mg once daily, for 7 - 10 days.
  • Skin and soft tissue infections: 250 - 500mg once or twice daily, for 7 – 14 days.

Dosage in patient with impaired renal function must be adjusted. No adjustment of dosage is required in patient with impaired liver functions, or elderly.

It may cause: Nausea, diarrhea, increases in liver enzymes. Tendon rupture.
Less frequency: urticaria, bronchospasm, anorexia, vomiting, abdominal pain, headache, dizziness, drowsiness and increase in bilirubin and serum creatinine.
Very rare: Confusion, psychotic reactions, angio-oedema, hypotension, tachycardia, tremor, anxiety, agitation, and confusion.

Hypersensitivity to levofloxacin or other quinolones, epilepsy, in patients with history of tendon disorders related to fluoroquinolone administration, children or growing adolescents.

The drug absorption is significantly reduced when iron salt, magnesium or aluminum containing antacids are administrated concomitantly with Tava-Floxacin. It is recommended that those preparations should not be taken two hours before or after Tava-Floxacin administration. A pronounced lowering of the cerebral seizure threshold may occur when the product is given concurrently with theophilline, non steroidal anti-inflammatory drugs, or other agents, which lower the seizure threshold. The half life of cyclosporin is increased by 33% when co-administrated with the drug.


  • The drug (as other quinolones) should be used with extreme caution in patients predisposed to seizures.
  • Diarrhea, particularly if severe, during or after treatment. The drug must be stopped immediately and patients must consult a doctor.
  • Caution should be exercised when the drug is co-administrated with drugs that affect the tubular renal secretion (such as probenecid and cimetidine), especially in renally impaired patient.

It should not be used in pregnancy or lactation.

Carton pack contains blister of 10 tablets with concentration of 250 or 500mg, with leaflet.


© 2010 Domina Pharmaceuticals